A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
Vulin M, Jehanno C, Sethi A, Correia AL, Obradović MMS, Couto JP, Coissieux MM, Diepenbruck M, Preca BT, Volkmann K, der Maur PA, Schmidt A, Münst S, Sauteur L, Kloc M, Palafox M, Britschgi A, Unterreiner V, Galuba O, Claerr I, Lopez-Romero S, Galli GG, Baeschlin D, Okamoto R, Soysal SD, Mechera R, Weber WP, Radimerski T, Bentires-Alj M.
Vulin M, et al. Among authors: britschgi a.
Oncogene. 2022 Sep;41(39):4459-4473. doi: 10.1038/s41388-022-02429-0. Epub 2022 Aug 25.
Oncogene. 2022.
PMID: 36008466
Free PMC article.